Business
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026Announced purpose-built commercial partnership with EVERSANA® to support potential U.S. launch of aglatimagene in localized prostate cancerCompany reported extended survival tail observed in trial of aglatimagene in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint
About this update from Candel Therapeutics, Inc.
[{"type":"image","alt":"Candel Therapeutics","displaySize":"","headline":null,"caption":"Candel Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":137,"url":"https://media.zenfs.com/en/globenewswire.com/e791e10481877ea34bb2d8e55bba5dfe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.UDl8bhJsgxnqpejVYBG6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Mg--/https://media.zenfs.com/en/globenewswire.com/e791e10481877ea34bb2d8e55bba5dfe","width":300,"height":137},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/.UDl8bhJsgxnqpejVYBG6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Mg--/https://media.zenfs.com/en/globenewswire.com/e791e10481877ea34bb2d8e55bba5dfe","width":300,"height":137}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026","length":185,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced purpose-built commercial partnership with EVERSANA® to support potential U.S. launch of aglatimagene in localized prostate cancer","length":139,"tagName":"p"}]},{"val":[{"type":"text","content":"Company reported extended survival tail observed in trial of aglatimagene in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint inhibitors (ICI)","length":192,"tagName":"p"}]},{"val":[{"type":"text","content":"Company to report extended follow-up data from the positive phase 3 clinical trial of aglatimagene in patients with localized, intermediate- to high-risk prostate cancer at the American Urological Association (AUA) 2026 Annual Meeting Plenary Program in May 2026","length":262,"tagName":"p"}]},{"val":[{"type":"text","content":"Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene in patients with progressive, metastatic, NSCLC despite ICI treatment, in Q2 2026","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash and cash equivalents of $194.8 million, as of March 31, 2026, are expected to be sufficient to fund the Company’s current operating plan into Q1 2028, which includes activities to support the potential commercial launch of aglatimagene in 2027","length":248,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":11...